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Summary
Objective: To compare synovial glucosamine levels in normal and inﬂamed equine joints following oral glucosamine administration and to de-
termine whether single dose administration alters standard synovial parameters of inﬂammation.
Methods: Eight adult horses were studied. On weeks 1 and 2, all horses received 20 mg/kg glucosamine hydrochloride by nasogastric (NG)
intubation or intravenous injection. On weeks 3 and 4, 12 h after injection of both radiocarpal joints with 0.25 ng Escherichia coli lipopolysac-
charide (LPS) to induce inﬂammation, glucosamine hydrochloride or a placebo was administered by NG intubation. Plasma samples were
collected at baseline and 5, 15, 30, 60, 120, 360, 480 and 720 min after dosing. Synovial ﬂuid (SF) samples were collected within 48 h before
dosing and 1, 6 and 12 h post-dosing. Glucosamine was analyzed by Liquid Chromatography Electrospray Tandem Mass Spectrometry (LC-
ESI/MS/MS). Clinicopathological evaluation of SF parameters included white blood cell (WBC) count and total protein (TP) analyses.
Results: No signiﬁcant differences between groups were observed in SF baseline levels of WBC and TP at any stage of the study. SF WBC
and TP signiﬁcantly increased following IA LPS. The mean (SD) maximal SF glucosamine levels (422.3 244.8 ng/mL) were signiﬁcantly
higher (>fourfold) in inﬂamed joints when compared to healthy joints (92.7 34.9 ng/mL). Glucosamine did not have any effect on standard
SF parameters of inﬂammation.
Conclusion: Synovial inﬂammation leads to signiﬁcantly higher synovial glucosamine concentrations compared to levels attained in healthy
joints following oral administration of glucosamine hydrochloride. Whether these higher levels are translated into a therapeutic effect on
the joint tissues remains to be elucidated.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is now known to be a slowly progressive
degenerative inﬂammatory process affecting the whole joint
organ including the synovial membrane, articular cartilage,
subchondral bone, ligaments and peri-articular tissues1.
New insights into the etiopathogenesis of OA and a better
understanding of the role of cytokines in these inﬂammatory
processes have permitted the identiﬁcation of pathways that
are potential targets for therapy2. Important advances have
been made in the symptomatic management of OA in
recent years, but the development of potent disease-
modifying OA is still elusive3.
Recent in vivo investigations in both humans and exper-
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228disease-modifying properties to glucosamine. Neverthe-
less, many issues concerning the efﬁcacy and therapeutic
target(s) of glucosamine still remain to be elucidated.
Most of the in vitro effects of glucosamine were observed
when supra-physiological concentrations were employed
that exceeded concentrations that are obtained in synovial
ﬂuid (SF) following oral consumption of glucosamine. Re-
cent publications have addressed this issue and revealed
beneﬁcial effects of glucosamine in vitro at biologically rele-
vant doses9e12. The glucosamine concentrations employed
in the latter experiments, approximate the plasma concen-
trations, but are still several times higher than the synovial
concentrations that can be obtained following oral glucos-
amine administration13,14.
In human osteoarthritic patients mean plasma glucos-
amine concentrations following repeated administration of
oral crystalline glucosamine sulphate at the current recom-
mended dose were w1.3 mg/mL (7 mM)14. In an equine
model maximum concentrations of serum glucosamine
following single nasogastric (NG) dosing of glucosamine
hydrochloride at 20 mg/kg reached w1 mg/mL (6 mM)13.
The SF concentrations in these studies reached w4 and
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respective plasma or serum concentrations13,14. The dis-
crepancy between glucosamine SF concentrations in the
human and equine study might be explained by a difference
in study design, by the use of different formulations of
glucosamine or the different bioanalytical methods em-
ployed in both studies14. Other possible explanations might
be species-related or due to the fact that in the former study
osteoarthritic joints were studied whereas in the latter
glucosamine concentrations were measured in clinically
normal joints.
In osteoarthritic joints, signiﬁcant synovial inﬂammation
can occur15e18 and a distinct pathogenic role of the syno-
vium in osteoarthritic cartilage degeneration has been sug-
gested15. In a recent magnetic resonance imaging (MRI)
study of patients with symptomatic knee OA, changes in sy-
novitis over time were correlated to changes in knee pain17.
These ﬁndings suggest that synovitis is likely to contribute
to ‘‘joint ﬂare’’, described as a substantial increase of an
individual’s pain and functional impairment within a limited
time period19. The permeability of the synovial membrane
and SF clearance of molecules are altered in the presence
of inﬂammation and may potentially affect glucosamine sy-
novial levels attained in the joint. Investigations of synovial
levels of anti-microbial drugs following parenteral adminis-
tration reported higher and more persistent concentrations
in inﬂamed compared to healthy joints20,21. However, in
contrast to these studies, an investigation of the intra-artic-
ular administration of amikacin in horses, revealed that sig-
niﬁcantly lower concentrations of the drug were present in
inﬂamed joints compared to normal22 underpinning the con-
cept that synovial inﬂammation alters compound inﬂux and
clearance from the joint.
The main objective of this study was to compare SF
levels attained in normal and inﬂamed equine joints follow-
ing oral administration of glucosamine hydrochloride. A sec-
ondary objective was to determine whether single dose
administration altered standard synovial parameters of
inﬂammation.MethodsMATERIALSGlucosamine hydrochloride (catalogue no. G1514, purity 99%), lipo-
polysaccharide (LPS) (catalogue no. L6526) and the internal standard (the-
ophylline) were purchased from SigmaeAldrich (St-Louis, MO, USA). Urea
reagents were obtained from Beckman Coulter Canada, Inc. (Mississauga,
ON, Canada). Other chemicals, including acetonitrile and formic acid were
purchased from J.T. Baker (Phillipsburg, NJ, USA).ANIMAL STUDIESPilot study to assess dose response to intra-articular (IA)
Escherichia coli LPS
Intra-articular E. coli LPS was used to create a mild to moderate synovitis.
This rapidly reversible model of joint inﬂammation is accompanied by mild
effusion without haematological changes but with SF changes consistent
with those found in acute synovitis23. In four adult horses, two doses of
LPS were evaluated to assess the response to IA LPS under our laboratory
conditions. The doses were based on doses previously reported in the
literature23.
Two groups (n¼ 2 per group) were injected in a radiocarpal joint with the
different doses of LPS. Chromatographically puriﬁed bacterial LPS, E. coli
O55:B5 was reconstituted with sterilized phosphate buffered saline (PBS;
pH 7.2) to achieve a stock concentration of 1 mg/mL. Dilutions from the
LPS stock concentration were prepared to yield individual doses of 0.5
and 0.125 ng/mL (corresponding to stock dilutions of 1:2,000,000 and
1:8,000,000, respectively). The IA injections were performed aseptically
with the LPS at the respective doses in a total volume of 1 mL using a tuber-
culin syringe and a 20-gauge (G) needle. SF was collected from theradiocarpal joint by aseptic arthrocenthesis with a 20-G needle immediately
before injection of LPS and at 1, 6, 12, 36 h and 7 days following injection.
EMLA anaesthetic cream (AstraZeneca, Mississauga, ON, Canada) was
applied 1 h prior to collection of the SF samples to desensitize the skin
and enhance animal compliance to the arthrocentesis procedures. The SF
samples were kept in an ethylenediaminetetraacetic acid (EDTA) tube at
room temperature for immediate clinicopathological evaluation. The evalu-
ated parameters included total nucleated cell count (TNC) with differential
and total protein (TP). Horses were evaluated clinically, by the same evalu-
ator (MM, DVM), at baseline and 6, 12, 24 and 36 h following the injection of
LPS. Subsequently, a clinical evaluation was performed every day for 1
week. The temperature, pulse, respiratory rate, attitude and appetite were
assessed. Joint effusion, warmth and resistance to palpation were subjec-
tively assessed at the same time. The grade of lameness was also deter-
mined using a standard scale of 0e5 lameness at the trot, with grade
0 as sound and grade 5 as non-weight bearing (AAEP lameness
classiﬁcation)24.
Principal study
Eight adult female horses, with a mean SD body weight of 459 42 kg
and a meanSD estimated age of 14.4 2.1 years were used in this study.
These animals were free of clinical evidence of joint disease (absence of
synovial effusion in target joint and no lameness attributable to this joint).
The principal study was executed over a 4-week period. On the ﬁrst week,
following a 12 h fast, all horses were administered glucosamine hydrochlo-
ride by NG intubation. On the second week, for the calculation of the phar-
macokinetic parameters of glucosamine in equine plasma only, all horses
were administered glucosamine hydrochloride by intravenous (IV) injection.
On the third and fourth week, following induction of short-acting, reversible
inﬂammation in both radiocarpal joints, NG intubation was repeated with
either glucosamine hydrochloride or an equivalent volume of saline, respec-
tively. Inﬂammation was induced by sterile intra-articular injection of 0.25 ng
E. coli LPS in both radiocarpal joints exactly 12 h prior to administration of
glucosamine or placebo. The LPS dose and the 12-h-lapse between induc-
tion of inﬂammation and time of glucosamine administration were selected
based on the results of the pilot study. Dilutions from the stock LPS concen-
tration were prepared to yield individual doses of 0.25 ng/mL (corresponding
to a stock dilution of 1:4,000,000). The injections were performed aseptically
with LPS at a dose of 0.25 ng in a total volume of 1 mL using a tuberculin
syringe and a 20-G needle.
Analytical-grade glucosamine hydrochloride was dissolved at 100 mg/mL
in 0.9% sterile saline and adjusted to a pH of 6.0. The ﬁnal solution was ﬁl-
tered through a 0.2 mm ﬁlter and administered at a dose of 20 mg/kg of body
weight by NG intubation or IV injection. NG dosing included 500 ml of 0.9%
sterile saline immediately after glucosamine administration. IV injection was
via a catheter inserted into the right jugular vein and was followed by
a 20 mL saline ﬂush to assure complete drug administration. Placebo con-
sisted of an equivalent volume of 0.9% saline administered by NG
intubation.
Blood samples were collected into EDTA tubes via an IV catheter in the
contralateral jugular vein and were obtained within 48 h before dosing and
at 5, 15, 30, 60, 120, 360, 480 and 720 min post-dosing. SF was collected
in two EDTA tubes by aseptic arthrocentesis at baseline (immediately before
injection of LPS) from both radiocarpal joints, at 1 and 12 h after administra-
tion of glucosamine from the left joint and 6 h post-dose from the right joint.
One EDTA tube was kept at room temperature and used for clinicopatholog-
ical evaluation of SF parameters including white blood cell count (WBC) with
differential and TP. The other EDTA tube and the blood samples were centri-
fuged within 30 min after collection at 1000g for 20 min and the cell-free su-
pernatants were removed and stored at 80C (for up to 8 weeks) until
assayed for glucosamine and urea.
In order to permit correction for possible dilutional effects, glucosamine
concentrations were analyzed before and after dilutional calculations as de-
scribed previously by Kraus et al.25 Brieﬂy, urea concentrations were as-
sessed in plasma and SF at baseline and 1 h following glucosamine
administration. From the relationship between plasma urea and synovial
urea concentrations at baseline, a dilution factor (DF) was calculated to cor-
rect the glucosamine concentrations attained 1 h post-glucosamine adminis-
tration for the effect of effusion in the LPS treated joints.
The animals were monitored clinically by the same evaluator as described
in the pilot study. Butorphanol tartrate (Torbugesic, Wyeth Animal Health,
Guelph, ON, Canada) was available as rescue medication for any animal
where discomfort was judged to be excessive. The experimental protocol
was approved by the Institutional Animal Care and Use Committee of the
University of Montreal.QUANTIFICATION OF GLUCOSAMINE FROM PLASMA AND SFThe concentrations of glucosamine in the plasma and SF samples were as-
sessed using Liquid Chromatography Electrospray Tandem Mass Spectrom-
etry (LC-ESI/MS/MS) using methods described previously26,27. The method
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validation guidelines published by the FDA inMay 200128. The inter-batch pre-
cision and accuracy ranged from 5.2 to 8.2% and 90.8 to 112.9%, respectively,
during the course of this study. The mean calculated coefﬁcient of correlation
(r) was 0.9979 for an analytical range set from10 to 1000 ng/mL. The analytical
method was adapted to analyze SF. Endogenous levels needed to be well es-
tablished during the analysis of samples to deﬁnemethod accuracy and recov-
ery. Pool SF samples with an endogenous level of 15.1 ng/mL (1.9) were
used to evaluate precision and accuracy. The reproducibility of the method
was evaluated by analyzing a minimum of six replicates of SF fortiﬁed at the
nominal concentration of 20, 40 and 60 ng/mL along with a calibration curve
made in saline solution [0.9% (w/v) NaCl in water]. In order to calculate the ac-
curacy, the endogenous level needed to be subtracted from the observed con-
centration of fortiﬁedSF [%NOM¼ [(measured concentration) (endogenous
concentration)]/(fortiﬁed concentration) 100]. The precision (%CV) and
accuracy (%NOM) observed ranged from 6.2 to 11.3 and 85.5 to 113.1 in
SF. According to the bioanalytical validation guidelines published by the
FDA inMay 200128, acceptable precision and accuracy results were achieved
for both matrices.QUANTIFICATION OF UREA IN PLASMA AND SFThe concentrations of urea in the plasma and SF samples were deter-
mined by a CX MULTI Calibrator (Synchron CX Systems, Beckman
Coulter Canada, Inc., ON, Canada). Concentrations were obtained by com-
pletely automated enzymatic reaction techniques and detection of the spec-
trophotometric change in absorption at 340 nm. The analytical range varied
between 1.8 and 35.7 mmol/L.PHARMACOKINETICSPharmacokinetic parameters of glucosamine in equine plasma were
calculated using non-compartmental methods29. The area under the
curve from time 0 to 12 h (AUC0e12 h) was calculated using a linear trap-
ezoidal rule. A terminal rate constant of elimination (kel) was calculated
using a minimum of three measurable plasma concentrations and the
terminal elimination half-life (T1/2) was calculated (T1/2¼ (ln 2)/kel). The
area under the curve extrapolated to inﬁnity (AUC0einf) was calculated
using AUC0e12 hþClast/kel, where Clast was the last measurable plasma
concentration.
After IV administration, the systemic clearance (CL) was calculated by
dividing the actual dose administrated by the AUC0einf. The mean resi-
dence time (MRT) was obtained by dividing the area under the ﬁrst mo-
ment-time curve (AUMC0einf) by the AUC0einf. The total volume of
distribution (Vd) was calculated using CLMRT. After NG administration,
the apparent clearance (CL/F ) was calculated by dividing the dose by the
AUC0einf. The maximal serum concentration (Cmax) and the time to attain it
(Tmax) were also determined. The bioavailability (F ) of glucosamine sul-
phate and glucosamine hydrochloride was calculated using the formula
(AUC0einf NG/AUC0einf IV) (DoseIV/DoseNG).STATISTICSFor the analysis of WBC, TP and glucosamine in the synovial liquid (pre-
and post-dilutional adjustments), a repeated-measures linear model was
used with treatment and time as within-subject factors. A priori contrasts
were used to compare mean values at different times within a treatment
and between treatments at each time period.Fig. 1. SF WBC count (A) and TP concentrations (B) in equine radiocarp
per grouResults
All procedures were well tolerated by the animals and no
adverse reactions were observed following the administra-
tion of glucosamine. Rescue medication was not required.
One horse alone, with a nervous temperament, was se-
dated prior to the arthrocentesis procedures.PILOT STUDY TO ASSESS DOSE RESPONSE TO IA E. COLI LPSClinical evaluation of the horses revealed no fever, tachy-
cardia or tachypnea at any time-point during the study. Clin-
ical signs following intra-articular LPS administration were
most pronounced at 6 h post-treatment. At this time-point,
horses that received 0.5 ng LPS IA were slightly depressed
and resisted joint manipulation. The treated joints exhibited
warmth, moderate joint effusion and a lameness grade of
3e4/5. In contrast, the horses that received 0.125 ng LPS
IA were alert 6 h after injection and showed no resistance
to joint manipulation. The treated joints were warm, had
only mild joint effusion and were attributed a lameness
grade of 1e2/5. Between 12 and 24 h post-injection, signs
of pain and lameness began to wane and were completely
resolved after 48 h.
The synovial WBC and TP concentrations of the individ-
ual horses at selected time-points are presented in Fig. 1.
A dose response was observed following LPS injection.
At baseline, synovial WBC concentrations ranged between
0.11 and 0.33 109 cells/L and TP concentrations between
9.0 and 24.0 g/L, for the two treatment groups. Monocytes
were the predominant population of the SF WBC differential
count at this time-point. The leucocyte concentrations
showed a dose-dependent increase and reached a maxi-
mum 6 h following IA administration of either of the two con-
centrations of LPS. Mean maximal WBC concentrations
were 164.59 109 cells/L following administration of
0.5 ng LPS and 11.06 109 cells/L following a dose of
0.125 ng LPS IA. At this time-point neutrophils were the pre-
dominant cell population of SF comprising 85e97% of the
total WBC differential. The TP concentrations were maximal
12 h post-LPS injection and mean concentrations of 58.5
and 32.0 g/L were obtained following IA administration of
0.5 or 0.125 ng LPS, respectively. After the peak, WBC
and TP concentrations declined progressively. Thirty six
hours after LPS injection, mean WBC concentrations for
the 0.5 and 0.125 ng LPS treatment group were
19.72 109 and 0.94 109 cells/L, respectively. At the
same time-point, the respective mean TP concentrations
were 33.5 and 26.5 g/L. Seven days following IA LPSal joints following IA injection of 0.125 or 0.5 ng E. coli LPS (n¼ 2
p).
Fig. 2. Mean (S.E.M.) SF WBC count (A) and TP concentrations (B) in normal or inﬂamed radiocarpal joints of horses (n¼ 8) following NG
administration of 20 mg/kg glucosamine hydrochloride or a placebo (arrow). Inﬂammation was induced 12 h prior to NG intubation by IA
injection of 0.25 ng E. coli LPS.
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baseline levels again.PRINCIPAL STUDYTable I
Mean (SD) and median (range) pharmacokinetic parameters of
glucosamine in equine plasma (n¼ 8) following IV administration
of 20 mg/kg glucosamine hydrochloride
Glucosamine hydrochloride
Mean (SD) Median (range)
AUC0e12 h, mg/h/L 51.16 (12.66) 53.62 (34.45e66.99)
AUC0einf, mg/h/L 52.28 (12.79) 55.41 (35.05e67.55)
T1/2, h 2.16 (0.35) 2.10 (1.68e2.60)
CL, L/h/kg 0.34 (0.09) 0.30 (0.25e0.47)
MRT, h 1.85 (0.34) 1.70 (1.43e2.37)
Vd, L/kg 0.62 (0.20) 0.66 (0.35e0.86)Based on the results of the pilot study, an intermediate
dose of 0.25 ng LPS IA was chosen to create the intra-artic-
ular inﬂammation, because we were not conﬁdent of a re-
peatable, minimal inﬂammatory response with the lowest
dose (0.125 ng LPS) tested in the pilot study. Furthermore,
the 12 h post-injection time-point was selected for com-
pound administration based on the SF inﬂammation param-
eter measurements. Speciﬁcally SF TP concentrations
were maximal at this point. We postulated that this was in-
dicative of maximal permeability of the synovial membrane.
Following injection of 0.25 ng LPS IA, none of the horses
exhibited any sign of systemic illness. Temperature, heart
and respiratory rate, attitude and appetite of all horses re-
mained normal throughout the 48 h following injection.
Treated joints were warm and had mild joint effusion. All
horses continued to bear weight on the injected limbs
throughout the 48 h following injection. Two horses ex-
hibited a grade of lameness of 3/5 6 h post-injection only.
The lameness grades in the remaining horses varied from
1 to 2/5. Between 12 and 24 h post-injection, signs of
pain and lameness began to wane and were completely re-
solved after 48 h. After induction of synovial inﬂammation
by IA injection with LPS, no difference in clinical evaluation
was noted following glucosamine administration compared
to placebo.
The mean synovial WBC and TP concentrations of the
horses in the three treatment groups are presented in
Fig. 2. At baseline, WBC and TP levels did not differ signif-
icantly between treatment groups and values were within
normal ranges of clinically healthy joints. Monocytes were
the predominant cell population in the SF TNC at this
time-point. IA injection of LPS resulted in signiﬁcantly in-
creased WBC and TP levels compared to baseline in both
the glucosamine and the placebo treated group. The
mean (SD) WBC concentration in the LPS treated joints
was 84.53 (42.34) 109 cells/L 1 h after the administration
of glucosamine compared to 87.22 (39.55) 109 cells/L
1 h post-placebo administration. At the same time-point, the
mean (SD) TP concentration for the respective treatment
groups was 49.6 (7.9) and 51.9 (5.9) g/L and in both
groups’ neutrophils were the predominant cell type. After
a peak at 1 or 6 h following administration of glucosamine
or a placebo, respectively, themeanWBCandTP concentra-
tions declined progressively, but were still signiﬁcantly higherthan baseline levels 12 h post-glucosamine administration.
Thedifference inmeanWBCandTPconcentrations between
the glucosamine and the placebo treated group was not sig-
niﬁcant at any time-point. In contrast to theWBC and TP con-
centrations in the LPS treated joints, these values were not
signiﬁcantly different from baseline at any time-point in the
healthy joints.
The descriptive statistics for the pharmacokinetic param-
eters of glucosamine in plasma after IV and NG dosing are
presented in Tables I and II, respectively. The mean plasma
glucosamine levels following NG administration of glucos-
amine hydrochloride in the presence and absence of syno-
vial inﬂammation are presented in Fig. 3(A). There were no
signiﬁcant differences in plasma glucosamine concentra-
tions between the two treatment groups at any of the
time-points. The mean synovial glucosamine concentra-
tions in the untreated and LPS treated radiocarpal joints fol-
lowing NG administration of glucosamine hydrochloride are
shown in Fig. 3(B). The endogenous glucosamine concen-
trations at baseline ranged from <10 (below limit of quanti-
ﬁcation) to 19.3 ng/mL and were not signiﬁcantly different
between the two treatment groups. The mean (SD) max-
imal SF glucosamine concentration was signiﬁcantly higher
(>fourfold) in inﬂamed radiocarpal joints with a mean (SD)
of 422.3 (244.8) ng/mL, when compared to levels in
healthy joints (92.7 (34.9) ng/mL). These values represent
43 and 9.9% of the mean maximal plasma concentrations
achieved in the same groups, respectively. Twelve hours
post-dosing mean (SD) SF concentrations were lowered
to 68.1 (41.0) and 12.3 (6.2) ng/mL, respectively, and
at this time-point they were no longer signiﬁcantly different
from baseline. The difference in SF concentrations of glu-
cosamine attained in healthy and LPS treated joints was
Table II
Mean (SD) and median (range) pharmacokinetic parameters of
glucosamine in equine plasma (n¼ 8) following NG administration
of 20 mg/kg glucosamine hydrochloride
Glucosamine hydrochloride
Mean (SD) Median (range)
AUC0e12 h, mg/h/L 3.23 (0.79) 3.36 (1.86e4.27)
AUC0einf, mg/h/L 3.47 (0.86) 3.60 (2.01e4.59)
Cmax, mg/mL 0.94 (0.27) 0.90 (0.58e1.30)
Tmax, h 0.81 (0.26) 1.00 (0.50e1.00)
T1/2, h 2.88 (0.80) 3.00 (1.80e4.10)
CL/F, L/h/kg 5.10 (1.54) 4.62 (3.61e8.27)
Bioavailability, % 6.90 (2.10) 6.10 (3.90e10.30)
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but not at 12 h (P¼ 0.34) post-glucosamine administration.
The urea concentrations at baseline ranged from 3.07 to
6.05 mmol/L in plasma and 3.5 to 7.16 mmol/L in SF. Linear
regression analysis of the urea concentrations in the
plasma and SF samples at baseline revealed a signiﬁcant
(P< 0.001), positive and linear relationship, where, joint
ﬂuid urea¼ [1.29 (plasma urea) 0.61]. The urea concen-
trations in the LPS treated joints at 1 h following glucos-
amine administration were used to correct glucosamine
concentrations for the dilution of the SF due to effusion by
determining the DF: DF¼ [1.29 (plasma urea) 0.61]/joint
ﬂuid urea. Glucosamine concentrations in LPS treated joints
at 1 h post-glucosamine administration were adjusted as
follows: glucosamineadjusted¼ (glucosamineinﬂamedDF).
However, there was no signiﬁcant difference in the glucos-
amine concentrations before and after correction.Discussion
Following oral administration of a clinically recommended
dose of glucosamine hydrochloride signiﬁcantly higher
concentrations of glucosamine were attained in joints with
induced synovial inﬂammation compared to healthy joints.
In the inﬂamed joints, the mean glucosamine concentra-
tions were up to fourfold higher than in the clinically normal
joints. The response to glucosamine treatment in OA pa-
tients may, therefore, in some way be related to the degree
of inﬂammation and the disease status of the affected joints.
The importance of synovitis in the pathophysiology of OA
is increasingly recognized. The spectrum ofFig. 3. Mean (S.E.M.) plasma (A) and SF (B) glucosamine concentration
amine hydrochloride (arrow) in the presence or absence of synovial in
administration by IA injection of 0.25 ng Ehistopathological alterations observed in the synovium
with different stages of OA has been previously described
and four different patterns of synovial reactions have been
recently identiﬁed15. One interesting ﬁnding is that the in-
ﬂammatory subform of osteoarthritic synoviopathy was
found in both the early and late stages of the disease pro-
cess and was characterized by moderate lymphocytic inﬁl-
trates, synovial hyperplasia and activation15. More
recently, analyses of synovial tissue samples harvested
from both early and late stage osteoarthritic joints revealed
an increased mononuclear cell inﬁltration, blood vessel for-
mation and overexpression of pro-inﬂammatory mediators
and nuclear transcription factors in early OA when com-
pared to late OA30 indicating that the intensity of inﬂamma-
tion in OA is greatest during the early phase.
Hypervascularity and dilatation of venules and arterioles
of the inﬂamed synovium may be associated with some de-
gree of synovial effusion, an increased protein concentra-
tion in the SF and an altered permeability to different
substances across the synovial membrane20e22. In the
present study, induced inﬂammation resulted in signiﬁcantly
higher synovial glucosamine levels compared to normal
joints following a single NG administration of glucosamine
hydrochloride. One could, therefore, hypothesize that in os-
teoarthritic joints, accompanied by considerable inﬂamma-
tion higher synovial glucosamine concentrations may be
obtained compared to joints with only mild or minimal in-
ﬂammation. The disease status of the studied joints may
thus be a confounding factor in a clinical trial on the use
of glucosamine in OA.
Laverty et al. were the ﬁrst to describe that glucosamine
enters the SF of clinically normal joints following NG admin-
istration of glucosamine hydrochloride in a large animal
model13. After a single dose administration of 20 mg/kg,
the synovial glucosamine concentrations in these joints
reached 0.3e0.7 mM. In the present study using the same
animal model, local inﬂammation resulted in synovial glu-
cosamine concentrations (422 244.8 ng/mL or 2.36
1.37 mM) that were fourfold higher than levels in healthy
joints (92.7 34.1 ng/mL or 0.52 0.19 mM). It could be ar-
gued that the clinical situation of ‘‘ﬂare up’’ recognized in
humans with OA represents acute bouts of inﬂammation.
However, to our knowledge, there is no information in the
literature on the synovial parameters of inﬂammation in
the presence of ‘‘ﬂare up’’. Although Persiani et al. have re-
cently reported glucosamine levels ranging from 3 to 18 mM
in human OA joints following oral administration of 1500 mg
crystalline glucosamine sulphate, once-a-day, for 14s in horses (n¼ 8) following NG administration of 20 mg/kg glucos-
ﬂammation. Inﬂammation was induced 12 h prior to glucosamine
. coli LPS in both radiocarpal joints.
233Osteoarthritis and Cartilage Vol. 17, No. 2consecutive days, no information was provided on the in-
ﬂammatory status of the joints14. A further study is needed
in humans to measure synovial glucosamine levels attained
in patients in a ‘‘ﬂare up’’ situation and compare them to
those attained in the less active inﬂammatory state. Other
possible explanations for the discrepancy between glucos-
amine levels in the equine and human studies may be spe-
cies related or related to the different analytical methods27
or different glucosamine formulations employed in the differ-
ent studies. It was suggested that a difference in glucos-
amine salts e hydrochloride vs sulphate e may result in
a different absorption of glucosamine and, therefore, in dif-
ferent synovial levels13. Indeed, a recent investigation from
our laboratory26 observed that following oral administration
of crystalline glucosamine sulphate to healthy, adult horses
signiﬁcantly higher synovial glucosamine levels are attained
when compared to an equivalent dose of glucosamine hy-
drochloride. However, mean maximal synovial concentra-
tions attained only 0.86 and 0.52 mM after a single dose
of crystalline glucosamine sulphate or glucosamine hydro-
chloride, respectively, and it was suggested that the differ-
ence in formulation (substances added to the sulphate
formulation), more than the difference in glucosamine salt,
may in some way be related to the beneﬁcial effects attrib-
uted to the glucosamine sulphate tested26.
In this study intra-articular injections of small doses of
E. coli LPS were used to induce a short-acting, reversible,
synovial inﬂammation as previously described by Palmer
and Bertone23. These authors reported that SF WBC count
and TP concentrations were linearly responsive to in-
creases in intra-articular LPS dosages up to 0.5 ng23.
Based on this information and on the results of our pilot
study to validate methods under our laboratory conditions,
an intermediate dose of 0.25 ng LPS was chosen, because
we were not conﬁdent of a repeatable, minimal inﬂamma-
tory response with the lowest dose (0.125 ng LPS) tested
in the pilot study. The resulting synovitis, following
0.25 ng LPS IA in this study, was characterized by mild ef-
fusion, joint warmth, mild pain on palpation and a low-
grade lameness. However, synovial WBC and TP concen-
trations were consistent with those found in acute and
severe synovitis and consequently it could be argued
that a limitation of this model of acute inﬂammation is
that it may not reﬂect chronic inﬂammatory processes
observed in osteoarthritic joints.
Although themean synovial leucocyte concentrations in the
LPS treated jointswere lower at 1, 6 and 12 h followingNGad-
ministration of glucosamine compared to administration of
a placebo, this difference was not statistically signiﬁcant.
Based on these ﬁndings a single dose administration of glu-
cosamine, in thepresenceof inﬂammation, doesnot alter stan-
dard clinical parameters of synovial inﬂammation. However, it
couldbeargued that this isahigh-hurdle test for anti-inﬂamma-
tory effects of a compound as it was tested in an acute, rela-
tively severe and rapidly reversible model of inﬂammation.
There are some limitations to the study. First, this is an
experimental animal model and caution should be exer-
cised when extrapolating ﬁndings to humans, particularly
as recent reports would appear to suggest that there may
be differences in synovial kinetics between humans and
horses14,26. Second, the inﬂammation induced was experi-
mental and rapidly reversible and though appealing from
a humane perspective for the animals, it does not accu-
rately mimic the situation in OA where inﬂammation, at least
in the advanced stages, is in general more chronic. Third,
we assessed only commonly used clinical parameters of sy-
novial inﬂammation in the study to detect anti-inﬂammatoryeffects of glucosamine as it was not the primary focus of this
investigation. Evaluation of additional parameters such as
SF prostaglandins (PG), leukotrienes, pro-inﬂammatory cy-
tokines, amongst others, and the introduction of a positive
control would be required to rule out a lack of anti-inﬂamma-
tory effects. Fourth, as we only used a single dose addi-
tional studies using repeated doses would be required to
shed light on whether joint levels attained could be altered
by repeated dosing as seen by others14 or whether inﬂam-
mation parameters could also be affected by repeated
doses.
Although there are some limitations to the study, these
ﬁnding translated into a clinical context, combined with
those of previous studies13,14,26, indicate that the maximal
glucosamine levels attainable in the SF in the presence of
inﬂammation are likely to be in the range of 1e18 mM for
both horses and humans. To date only one in vitro study
has demonstrated beneﬁcial effects of glucosamine on car-
tilage using these concentrations11. Speciﬁcally, it was
shown that treatment of OA chondrocytes with glucosamine
sulphate at concentrations of 1e150 mM resulted in a dose-
dependent increase in aggrecan core protein levels and
a reduction of matrix metalloproteinase-3 (MMP-3) produc-
tion and activity11. It is also possible, however, that glucos-
amine exerts its beneﬁcial effects on either the synovial
membrane or other peri-articular structures including the
subchondral bone5 or soft tissues of the joint such as the
joint capsule or ligaments31 and that the plasma levels
rather than the synovial levels are more relevant to the de-
bate on its action. In human osteoarthritic patients, maximal
plasma glucosamine concentrations up to 23 mM were re-
ported following oral administration of a clinically recom-
mended dose of glucosamine sulphate14. At a slightly
higher concentration (28 mM), glucosamine hydrochloride
regulated gene expression and synthesis of NO and
PGE2 in bovine articular cartilage explants stimulated with
Interleukin-1 (IL-1), providing evidence for the anti-inﬂam-
matory properties of glucosamine at these concentra-
tions10. Higher maximal plasma concentrations of
glucosamine (up to w10 mg/mL or 56 mM) were reported
in dogs32 and horses33 after oral administration of 5e10
times the typical administration levels to these species. In
a study on plasma glucosamine levels in humans it has
been questioned, however, whether augmenting the dose
is clinically advantageous, since doses higher than the clin-
ically recommended dose produced proportionally lower
plasma concentrationetime proﬁles34. It is also conceivable
that glucosamine has some as yet un-identiﬁed beneﬁcial
effects on joint tissues at reported in vivo concentrations
in both SF and plasma that explain positive results in clinical
trials.
We conclude that synovial inﬂammation leads to signiﬁ-
cantly higher synovial glucosamine concentrations
compared to healthy joints following oral administration
of a clinically recommended dose of glucosamine hydro-
chloride. Further studies are needed in humans to measure
synovial glucosamine levels attained in patients in a ‘‘ﬂare
up’’ situation and compare them to those attained in the
less active inﬂammatory state.Conﬂict of interest
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